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DARPin inhibitors
Abstract
The multidrug exporter AcrB is the inner membrane component of the AcrAB-TolC drug efflux system
in Escherichia coli and is responsible for the resistance of this organism to a wide range of drugs. Here
we describe the crystal structure of the trimeric AcrB in complex with a designed ankyrin-repeat protein
(DARPin) inhibitor at 2.5 A resolution. The three subunits of AcrB are locked in different
conformations revealing distinct channels in each subunit. There seems to be remote conformational
coupling between the channel access, exit, and the putative proton-translocation site, explaining how the
proton motive force is used for drug export. Thus our structure suggests a transport pathway not through
the central pore but through the identified channels in the individual subunits, which greatly advances
our understanding of the multidrug export mechanism.
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Introduction
Drug resistance is a medical problem, ranging from cancer
cells evading chemotherapy to bacteria surviving antibiotic
treatment. Efﬂux pumps represent one class of integral
membrane transport proteins in bacteria that confer anti-
biotic resistance [1]. These proteins actively detoxify the
intracellular space by exporting drugs to the cell exterior.
AcrB of Escherichia coli is such an efﬂux pump belonging to the
subclass of resistance-nodulation-cell division transporters,
which catalyze drug export driven by proton antiport [2].
AcrB associates with the outer membrane channel TolC [3]
and the periplasmic protein AcrA [4] and allows direct and
efﬁcient transport of a wide range of toxic substances [5]. The
structures of AcrB alone [6] and of AcrB in complex with
substrates [7,8] revealed the general architecture of the
transporter. However, despite all mutational and structural
studies to date, the mechanism explaining how substrates are
transported into the extracellular media was still unclear.
The use of antibody fragments as crystallization aids for
membrane proteins has yielded a number of crystal struc-
tures [9,10]. The binding of such antibody fragments enlarges
the hydrophilic extramembranal surface of integral mem-
brane proteins, thereby providing additional surface for
crystal contacts. They can also stabilize a speciﬁc conforma-
tion supporting the crystallization process. The drawback of
the antibody fragment approach is that it is not always easy to
get an antibody fragment that recognizes and binds to a
particular conformation of a membrane protein. Further, the
selected antibody fragment might be unstable or production
might be difﬁcult. To circumvent these problems, we applied
an approach based on designed ankyrin-repeat proteins
(DARPins) as an alternative to antibody fragments. DARPins
can be selected to bind almost any given target protein with
high afﬁnity and speciﬁcity [11]. They are very stable and can
be produced as soluble proteins in large amounts by bacterial
expression. As DARPins interact with their target protein
with an exposed interaction surface, they tend to bind to
conformational epitopes rather than to peptidic ones. These
characteristics make DARPins ideal tools to help the
structural studies of membrane proteins.
Here we selected DARPins that not only bind to AcrB but
also inhibit bacterial drug export. Crystals of a selected AcrB–
DARPin complex were obtained, and the structure was
determined at 2.5-A˚ resolution. It is the ﬁrst structure of an
integral membrane protein with a selected DARPin molecule
binder. The structure reveals a previously unknown asym-
metric conformation of the efﬂux pump, in which each of the
three subunits has a unique well-deﬁned conformation. The
internal asymmetry of AcrB is underlined by the fact that
only two of the three subunits of AcrB are recognized by
DARPins in crystallo and in solution and is in contrast to the
3-fold symmetric structures reported to date [6–8]. The
structural features described here together with the enhanced
resolution allow us to deduce a pathway for drug export and a
mechanism for the coupling of substrate export with proton
import.
Results
DARPin Selection and Inhibitor Screening
DARPin binders were selected in vitro by ribosome display
using a designed ankyrin-repeat protein library [11,12]. The
selection was performed on puriﬁed and in vitro biotinylated
AcrB under native conditions. Four rounds of ribosome
display were sufﬁcient to select a pool of speciﬁc DARPins
binding to AcrB. These experiments are to our knowledge the
ﬁrst ribosome display selections performed in the presence of
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detergent to select speciﬁc binders to an integral membrane
protein.
The pool of speciﬁc binders was subjected to an in vivo
screen, based on replica plating, to identify those AcrB-
binding DARPins which lead to an inhibitory phenotype. As
AcrB is crucial for the transport of certain substrates, its
inhibition will consequently lead to accumulation of sub-
strates in the bacterial cell and consequently to cell death. We
chose Rhodamine 6G (R6G) as substrate for AcrB. The
enriched pool after four rounds of ribosome display was
cloned into an expression plasmid under the control of an
isopropyl-b-D-thiogalactopyranoside (IPTG)-inducible pro-
moter. E. coli strain XL1-blue was transformed and plated
under nonselective conditions, in absence of R6G. About
1,500 colonies were subsequently replica-plated under selec-
tive conditions, in the presence of 32 lg/ml R6G. By this
procedure, 18 single clones were identiﬁed which showed a
rhodamine-sensitive phenotype. These selected clones were
sequenced and assayed for expression. Analysis of the
sequences showed that all 18 clones were different and
unique.
The afﬁnities of the AcrB inhibiting DARPins were
analyzed by surface plasmon resonance using a BIAcore
(http://www.biacore.com) instrument. The analysis was per-
formed on AcrB-coated sensor surfaces with multiple con-
centrations of the DARPins and was evaluated with a global
kinetic ﬁt. The ﬁve inhibitors with highest afﬁnity, having
dissociation constants in the low nanomolar range (3.6 to 98.9
nM; Figure S1), were chosen for further characterization.
Clone 1108_19, which was used for cocrystallization, had a
dissociation constant KD of 28 nM.
Inhibition Efficiency of the DARPins
We rated the inhibition efﬁciencies of the identiﬁed
DARPins by spotting the clones onto selective plates with
different R6G concentrations, ranging from 2 to 64 lg/ml
(Figure 1). All inhibitors showed a signiﬁcant increase of the
sensitivity compared to cells expressing an unselected non-
binding DARPin, termed E3_5 [13]. This control also showed
that the expression of a nonbinding DARPin per se has no
inﬂuence on R6G sensitivity or bacterial growth. The acrB
gene-deletion strain KAM3 [14] causes hypersensitivity to
R6G and was used as a sensitivity control. In absence of R6G,
DARPins conferring R6G sensitivity did not inﬂuence E. coli
growth by themselves. It should be noted, however, that the
afﬁnity of the inhibitors does not always correlate with the
inhibition efﬁcacy (Figure S1). Possible factors leading to this
observation include different expression levels or different
binding sites of the DARPins on AcrB. Moreover, the exact
inhibition mechanism is not known, even for the inhibitor
1108_19 for which the structure was solved. Different
inhibition mechanisms seem plausible ranging from allosteric
inhibition of the rotary export mechanism of AcrB by the
DARPin to simply preventing the interaction with TolC or
AcrA to form the export complex.
Overall Structure of the AcrB–DARPin Complex: Loss of
the 3-Fold Symmetry
AcrB exists as a homotrimer, with each subunit containing
12 transmembrane (TM) helices and a large periplasmic part
formed by two loops between TM helices 1 and 2 and TM
helices 7 and 8. The trimer consists of three prominent
domains, the TM domain, and parallel to the membrane, the
adjacent pore domain and the TolC docking domain (Figure
2A). The TM domain encompasses a large central cavity, 35 A˚
in diameter, through the membrane which is closed toward
the central funnel formed by the TolC docking domain by
three helices provided by the PN1 subdomains of the pore
domain (Figure 2B and 2C). The export of substrates was
proposed directly through this central pore. Several struc-
tures of ligand-free AcrB and with bound substrates have
been solved at moderate resolution (between 3.5 and 3.8 A˚).
Yu et al. [7,8] reported structures of AcrB–ligand complexes
showing ligand binding to the upper wall in the central cavity
and additional substrate binding in the periplasmic domain,
compatible with mutational studies, which indicated that
discrimination between different toxic substrates occurs in
the periplasmic domain, rather than in the TM domain
[15,16]. All structures determined to date imply 3-fold
symmetry and thus the three AcrB subunits displayed the
same conformation.
To analyze the interaction and to characterize the
inhibition property of a selected DARPin, we determined
the crystal structure of one inhibitor (1108_19) in complex
with AcrB. The crystals diffracted to 2.5-A˚ resolution and
belonged to space group P212121. The structure was solved by
molecular replacement using the structure published by
Murakami et al. [6] as a search model without using the phases
of the DARPin. The results of the data collection and
reﬁnement are presented in Table 1.
The crystal structure of the AcrB–DARPin complex shows
two DARPin molecules bound basically to two subunits,
named A and B, in the homotrimeric transporter, while the
third subunit, named C, is not bound (Figure 2A and 2B).
Unlike previously determined crystal structures, there is no 3-
fold symmetry of AcrB with the DARPin molecules stabilizing
three distinct conformations of the subunits. The conforma-
tions of the DARPin-bound subunits A and B are similar to
the known symmetric structure. A superposition on Protein
Data Bank entry 1IWG [17] shows a few differences for these
Author Summary
Bacterial resistance to antibiotics is a major challenge for the current
treatment of infectious diseases. One way bacteria can escape
destruction is by pumping out administered drugs through specific
transporter proteins that span the cell membrane. We used designer
proteins that bind to and stabilize proteins of interest in order to
study the major drug efflux pump of Escherichia coli, AcrB. After
selecting for designed ankyrin repeat proteins (DARPins) that inhibit
this pump, we determined the crystal structure of a DARPin inhibitor
in complex with AcrB. We confirmed that the AcrB is split into three
subunits, each of which exhibits distinctly different conformations.
Moreover, we show that each subunit has a differently shaped
substrate transport channel; these variable channels provide unique
snapshots of the different conformations adopted by AcrB during
transport of a substrate. The structure also offers an explanation for
how substrate export is structurally coupled to simultaneous proton
import—thus significantly improving our understanding of the
mechanism of AcrB. This is the first report of the selection and co-
crystallization of a DARPin with a membrane protein, which
demonstrates the potential of DARPins not only as inhibitors but
also as tools for the structural investigation of integral membrane
proteins.
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two subunits with root-mean-square deviations of 1.72 A˚ and
1.98 A˚, respectively, for 1,033 Ca atoms, compared to 2.95 A˚
for the third subunit C. To validate in solution the 3:2 (AcrB
monomer to DARPin) stoichiometry observed in the crystal
structure, we performed sedimentation velocity experiments.
Single molecular weight species taking the detergent micelle
into consideration were observed, with molecular masses of
374 6 1.6 kDa for AcrB alone and 408 6 1.7 kDa for the
complex (Figure S2). The mass difference indicates that AcrB
in solution is bound by two DARPins, with a calculated mass
of 17.8 kDa each.
As can be seen in the crystal structure (Figure 2A and 2B),
the DARPins bind mainly to the b-sheet connecting the pore
domain with the TolC docking domain interacting, as
expected, primarily through their randomized concave sur-
face area. The interface buries a surface of around 1,000 A˚2
(see Table S1 for detailed interactions). Furthermore, each
DARPin interacts with the adjacent preceding subunit of
AcrB via one additional hydrophobic interaction involving
Leu230 of the intersubunit connecting loop as well as two
interactions involving the residues Arg263 and Lys248, again
of the preceding subunit (Table S1). Subunit C is in a
different orientation, and consequently no DARPin is bound.
Notably, the DARPins not only stabilize the asymmetric
conformation of AcrB but are also involved in direct
interactions in the crystal lattice (Figure S3), resulting in a
different crystal form P212121.
Structure Reveals Channels Leading through the
Individual Subunits
The three AcrB subunits are bound in three different
conformations, revealing three distinct channels (Figure 3).
The width of these channels is sufﬁcient for the passage of
typical AcrB substrates. In subunit A, a channel is observed,
extending from the external depression through the large
periplasmic domain reaching almost the central funnel at the
top of the protein (Figure 4A). Here the side chains of
residues Gln124, Gln125, and Tyr758 form a gate, closing the
channel and therefore preventing direct access to the central
funnel. The periplasmic channel entrance corresponds
perfectly with the periplasmic binding site indicated in the
AcrB–ligand structures of Yu et al. [8]. A similar channel,
although a little wider, is present in subunit B (Figure 4B). In
addition, the channel is open not only to the periplasm but
also to the membrane bilayer at the periphery of the TM
domain. In subunit C, the channel entrances are closed due to
movements of PC2 and PN1 (Figure 4C). In contrast to
subunits A and B, the gate to the central funnel at the top of
the periplasmic domain formed by residues Gln124, Gln125,
and Tyr758 is now open, allowing the substrate to enter the
central funnel from where it most probably reaches TolC and
is exported to the cell exterior.
Structural Rearrangements in the Putative Proton-
Translocation Site
The opening and closing of the channel entrances and the
gate is coupled to structural rearrangements in the putative
proton-translocation site in the TM domain (Figure 5A)
involving residues in the middle of the TM helix 4 (Asp407
and Asp408) and TM helix 10 (Lys940), respectively (Figure
5B). These charged residues are localized in the center of the
hydrophobic TM domain and have been shown to be essential
for the proper function of AcrB, since the mutation of these
residues leads to complete loss of drug resistance [18]. In
subunits A and B, Lys940 forms a salt bridge to the side chains
of Asp407 and Asp408, which are also involved in H-bonds
with Ser481 and Thr978 presenting the same conformation
described to date [6]. In subunit C, this salt bridge is not
formed; instead Lys940 is tilted away, forming new polar
contacts to Asn941 and Thr978.
Figure 1. Phenotype of E. coli XL1-Blue Strain Expressing the Selected Inhibitory DARPins
Six AcrB inhibitors (2907_5, 1108_5, 1108_6, 1108_9, 1108_19, and A11), one unselected nonbinding DARPin (E3_5), and an acrB knockout strain (KAM3
[14], transformed also with E3_5) were ranked for their R6G sensitivity. Induction of the DARPins results in the inhibition of AcrB, yielding an R6G-
sensitive phenotype. E. coli cells were transformed with the respective plasmid and plated under different conditions: nonselective, no R6G or no IPTG;
selective where different R6G concentrations create an environment in which inhibitory DARPins repress growth. All plates contained IPTG (except plate
no IPTG). The plates were colored with Coomassie brilliant blue for better visibility of the colonies.
doi:10.1371/journal.pbio.0050007.g001
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The conformational changes described for the putative
proton-translocation site are linked to the opening and
closing of the channel entrances and the gate described above
via rigid movements of TM helix 5 and TM helix 8 (Figure
5A). Distinct conformational differences of the polypeptide
stretch that connects the N-terminal end of TM helix 8 to PC2
can be observed in each subunit (Figure 4). The functional
importance of this connection is underlined by the fact that
each subunit displays a different conformational state of this
polypeptide stretch. In subunit A, the stretch shows a long
random coil conformation, whereas in subunit B, it adopts
partially a helical conformation but with still some random
coil conformation. In subunit C, the polypeptide segment is
in a completely a-helical conformation continuing the TM
helix 8 up to the headpiece subdomain PC2.
The loss of the interaction of Asp407, Asp408 with Lys940
in the putative site for proton-translocation, the simulta-
neous closing of the channel entrances, and the opening of
the gate are evident. This hints at a coordinated control or a
coupling of drug export and proton-translocation. The
coupling seems to occur via the polypeptide segment that
connects TM helix 8 and PC2.
Comparison of Asymmetric AcrB Structures
During the review process of this manuscript, the asym-
metric structure of AcrB was published by two other groups
[19,20]. Our experimental approach, however, differs from
theirs as we apply a new technology using DARPins as
crystallization aid. This lead to a new crystal form, P212121,
and, ﬁnally, crystals diffracting to higher resolution. Notably,
the structural comparison reveals that all three independent
structure determinations of AcrB resulted all in almost
identical structures. The root-mean-square deviations for
1,032 Ca atoms (Table S2 and Video S1) is around 1, which is
a very good correlation at the given resolutions of the
different structures (2J8S, 2.5 A˚; 2DHH, 2.8 A˚ [19]; 2GIF, 2.9 A˚
[20]). Importantly, the region where the DARPins bind shows
no signiﬁcant differences in all the structures. This clearly
demonstrates that the selected DARPins bind and stabilize an
existing conformational state and do not induce a nonnative
conformation upon binding. Murakami et al. [19] also
crystallized the protein in the presence of two substrates,
which greatly substantiates our ﬁndings. In conclusion, all
three crystal structures lead to virtually identical conclusions
Figure 2. Crystal Structure of the AcrB–DARPin Complex
(A) Ribbon diagram of the overall AcrB–DARPin complex structure viewed from the side, depicted in three different colors for each subunit: green, blue,
and yellow for A, B, and C, respectively. The DARPins are colored in red. This color code is used throughout all the figures. The locations of the three
prominent domains are indicated and the important regions are highlighted and labeled in subunit C (G, gate; ED, external depression; P, putative
proton translocation site; H, helix 8).
(B) Ribbon diagram of the overall AcrB–DARPin complex viewed from the periplasm.
(C) Ribbon diagram of the pore domain viewed as in (B). The subdomains are labeled.
All figures of the molecular models were generated with PyMOL [31].
doi:10.1371/journal.pbio.0050007.g002
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about the drug export pathway and we all proposed similar
export mechanisms.
Discussion
Cocrystallization of the membrane protein AcrB and a
DARPin inhibitor selected from a large combinatorial library
resulted in crystals that diffract to high resolution. The
signiﬁcant higher resolution of our structure compared to
the structures published to date allowed unambiguous
modeling of the side chain conformations and the interpre-
tation of structural rearrangements extending from the
putative proton-translocation sites in the center of the
membrane to the gate in the periplasmic domain. The quality
of the structure is underlined by 11 resolved detergent
molecules (Figure S4). Our work shows for the ﬁrst time the
structure of an integral membrane protein with a selected
DARPin molecule, an experimental approach that has great
potential for the structural biology of these exceedingly
difﬁcult proteins. DARPins may aid by stabilizing certain
conformations and by extending the hydrophilic surface
similar to antibody-derived protein fragments.
In contrast to the previously known R32 crystal form of
AcrB with one monomer in the asymmetric unit, in our
structure there are one AcrB trimer and two DARPins in the
asymmetric unit, and therefore there are no constraints
regarding the conformation of the individual subunits of
AcrB. Indeed, the crystal structure shows different confor-
mations for the three individual subunits and reveals
channels extending either from the periplasm and the
membrane bilayer to a gate near the central funnel at the
top of the protein or as in one subunit extending from the
gate directly into the central funnel. Moreover, we were able
to conﬁrm the 3:2 stoichiometry in solution, conﬁrming the
internal asymmetry of AcrB. We believe that the three
conformations likely present intermediates in the transport
cycle and suggest a rotary mechanism for drug transport
where the three subunits strictly alternate their conformation
in a concerted way (Figure 6). The R6G-sensitive phenotype
of cells expressing the DARPin supports this hypothesis. AcrB
may be locked by the DARPins and therefore the rotation of
the molecule is stopped. It seems unlikely that the subunits
export drugs independent of each other. If this was the case,
subunit C would still be functional, and this would be in
contrast to the observed inhibitory phenotype induced by the
DARPin. Another possibility for the inhibitory effect of the
DARPin is that either TolC or AcrA is unable to bind AcrB
Table 1. Data Collection and Refinement Statistics
Method Parameter AcrB/1108_19
Data collection Space group P212121
Unit cell parameters (A˚) a ¼ 146.18, b ¼ 157.41, c ¼ 246.04
Resolution (A˚) 35.00–2.54 (2.70–2.54)a
Completeness (%) 95.0 (79.9)
Rmerge
b 0.081 (0.321)
I/r(I) 20.75 (6.1)
Refinement Resolution 25.00–2.54 (2.70–2.54)
Number of reflections 177,557
R/Rfree (%)
c 22.9/27.0
RMS deviations
Bond lengths (A˚) 0.008
Bond angles (8) 1.3
Ramachandran plot (%)
Most favored 88.4
Allowed 10.8
aValues in parentheses are for the highest resolution shell.
bRmerge ¼
P
h
P
j j,I.h  Ih,jj/
P
h
P
jIh,j, where ,I.h is the mean intensity of symmetry-
equivalent reflections.
cR ¼PjFobs  Fcalj/
P
Fobs. The formula for Rfree is the same as that for R, except it is
calculated with a portion of the structure factors that had not been used for refinement.
doi:10.1371/journal.pbio.0050007.t001
Figure 3. Channels in the AcrB Trimer
Stereo view of the channels leading through the periplasmic domain of AcrB. The structure of AcrB is shown as wire model and the DARPins omitted for
clarity. The channels are shown as blue surfaces and were calculated using the program CAVER (http://loschmidt.chemi.muni.cz/caver).
doi:10.1371/journal.pbio.0050007.g003
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anymore, resulting in the loss of function of this resistance-
nodulation-cell division–type transport protein.
We believe that AcrB operates through a mechanism
resembling the alternating-access mechanism which is the
substrate-translocation mechanism most commonly de-
scribed to secondary membrane transporters [21]. We
propose that substrates could enter the channel in subunit
B via the transmembranal groove at the periphery of the TM
domain or via the external depression in the periplasmic part
of the structure close to the outer leaﬂet of the membrane.
Substrate would then be speciﬁcally bound with the gate of
the channel still closed to the central funnel at the top of the
periplasmic headpiece. Upon protonation of the proton
gating residues Asp407 and/or Asp408, conformational
changes in the TM helix 8 take place, which in turn trigger
the conformational changes in the periplasmic headpiece.
The channel entrances then close through movements of
subdomains PN1 and PC2 opening the gate toward the
central funnel at the top of the headpiece, releasing the
bound substrate into the funnel, from where it could reach
TolC and ﬁnally the cell exterior.
Figure 4. The Extension of the Channels in the Individual Subunits of AcrB
The view is the same as in Figure 2A. For simplicity, the DARPins are not shown. The channels are colored in transparent blue. The potential export
pathway is represented by dashed lines. The loop forming the bottom of the periplasmic channel entrance (PE) and TM helix 8 are highlighted in red.
The gate to the central funnel formed by the residues Gln124, Gln125, and Tyr758 is shown in space filling representation for clarity.
(A) In subunit A, the channel is opened to the periplasm, while the gate is in the closed conformation. The pore domain subdomains are labeled.
(B) In subunit B, the channel displays an open conformation to the periplasm and to the membrane bilayer (CE). The gate is in a closed conformation.
(C) Subunit C displays a closed conformation of the channel entrances, while the gate is open, extending the channel to the central funnel.
doi:10.1371/journal.pbio.0050007.g004
Figure 5. Conformational Changes in the TM Region of AcrB
(A) Wire model of the superpositioned TM domains of subunit A and
subunit C viewed from the periplasmic side. Subunit B is omitted since it
displays a similar conformation as subunit A. The individual helices are
labeled.
(B) Detailed interactions of the amino acid residues in the putative
proton-translocation site viewed in the same orientation as in (A).
Residues involved in the hydrogen-bonded network (dashed lines) are
labeled. The jFo-Fcj omit electron density map (blue mesh) of Lys940 in
subunit C is contoured at 3.5 r.
doi:10.1371/journal.pbio.0050007.g005
Figure 6. Schematic Drawing of the Transport Pathway of the AcrB Efflux
Pump Suggesting a Rotary Mechanism
Proposed mechanism: Substrate may bind into the channel through the
open entrances of subunit B. Helix 8 is only weakly pronounced and
mostly random coil. Changes of the protonation state of residues of the
putative translocation site induce the formation of helix 8 and thus the
closing of the channel entrances and the simultaneous opening of the
gate, extending the channel to the central funnel at the top of the
headpiece showing the conformation of subunit C. The bound substrate
can be released into the central funnel from where it reaches TolC and
finally the cell exterior. Deprotonation takes place, leading to the
collapse of helix 8, and the channel goes back to the original
conformation (subunit A).
doi:10.1371/journal.pbio.0050007.g006
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While this model is based on the interpretation of the
structural information seen in the asymmetric structure, it
contains all features necessary for the export of substrates
and simultaneous import of protons. It is also consistent with
mutational studies available to date [8,17]. Further experi-
ments using the crystals of the complex with drug substrates
may substantiate this mechanism. In fact, similar to the
experiments performed by Murakami et al. [19], we also could
show binding of minocycline in the identiﬁed channel at 2.5-
A˚ resolution (unpublished data). The structural ﬁndings most
likely rule out the previously proposed export of substrates
directly through the central pore of the structure.
Materials and Methods
AcrB production and puriﬁcation. AcrB was overexpressed in E. coli
strain BL21 (DE3; Novagen, EMD Biosciences, http://www.
emdbiosciences.com) overnight at 30 8C using a pET28 vector
(Novagen) containing acrB with a hexahistidine-tag at the C terminus.
Cells of 1-L bacterial culture were disrupted with a French pressure
cell, and the membranes were collected and solubilized in buffer A
(20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 10 mM imidazole, 10%
glycerol), containing 1% (w/v) n-dodecyl-b-D-maltoside (DDM) (Ana-
trace, http://www.anatrace.com). Lipids and debris were removed by
ultracentrifugation at 100,000g for 1 h. The solubilized protein was
puriﬁed with afﬁnity chromatography using Ni-NTA (Qiagen, http://
www.qiagen.com), equilibrated with buffer A, containing 0.03%
DDM. The column was washed using this buffer and 50 mM imidazole,
respectively. Puriﬁed AcrB was eluted with 200 mM imidazole added
to the above buffer.
For biotinylation purposes, AcrB was eluted in 200 mM imidazole
(pH 7.5) as the only buffering agent. The protein was chemically
biotinylated using a 15 molar excess EZ-Link Sulfo-NHS-LC-Biotin
(Pierce Biotechnology, http://www.piercenet.com) for 30 min at 4 8C.
Free biotin was removed using a HiTrap Desalting column (5 ml;
Amersham Biosciences, http://www.amersham.com) equilibrated in
buffer B (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.03% [w/v] DDM).
In vitro selection by ribosome display. Four rounds of ribosome-
display selection were carried out using an N3C DARPin library
[11,12]. In vitro biotinylated AcrB was immobilized on neutravidin-
coated wells blocked with BSA. To eliminate BSA- and neutravidin-
binding library members as well as further unspeciﬁc binders, two
pre-panning steps were applied, where neutravidin, BSA, and
biotinylated maltose binding protein (MBP) [11] were present. In
the actual panning step, binders to AcrB were thus selected. The
panning procedure was performed exactly as described previously
[11], with the modiﬁcation that all buffers contained 0.03% (w/v)
DDM, to keep AcrB stable and solubilized.
In vivo selection by replica plating. The pool of speciﬁc binders was
subjected to an in vivo screen, based on replica plating, to identify
those AcrB-binding DARPins with an inhibitory phenotype. For this
purpose, the selected pool of binders was cloned into the vector pQIA
[22]. This vector carries an expression cassette for the selected
DARPins under the control of an IPTG-inducible T5 promoter.
The pool of binders was transformed into E. coli XL1-blue cells
(recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F9 proAB
lacIqZDM15 Tn10 (Tetr)]; Stratagene, http://www.stratagene.com) and
plated under nonselective conditions (ampicillin, IPTG, no R6G).
About 1,500 colonies were subsequently replica-plated under
selective conditions (ampicillin, IPTG, R6G [32 lg/ml]). By this
procedure, 18 N3C clones were identiﬁed which showed a rhod-
amine-sensitive phenotype. The characterization of these DARPins
included sequencing, expression tests, surface plasmon resonance,
MIC determination, size exclusion chromatography studies, and
cocrystallization.
Drug susceptibility assay. The susceptibility to R6G of E. coli XL1-
blue cells expressing the selected DARPins were determined by
sequential 2-fold dilutions with LB agar/glucose plates containing 0.1
mM IPTG. R6G was used at concentrations of 2, 4, 8, 16, 32, and 64 lg/
ml. Bacterial growth was examined after 24 h at 37 8C.
Surface plasmon resonance. Surface plasmon resonance was
measured using a BIAcore 3000 instrument at 20 8C. The running
buffer was buffer B. An SA chip (BIAcore) was used with 700 RU of
biotinylated AcrB immobilized. The DARPin binding was measured
at a ﬂow of 50 ll/min with 5-min buffer ﬂow, 2-min injection of AcrB-
binding DARPin in varying concentrations (2.5 nM to 60 nM), and an
off-rate measurement of 30 min with buffer ﬂow. The signal of an
uncoated reference cell was subtracted from the measurements. The
kinetic data of the interaction were evaluated using the program
BIAevaluation 3.0 (BIAcore), and global ﬁts were used to determine
KD. The possible avidity effect of the AcrB trimer was not taken into
account in the ﬁt.
Analytical ultracentrifugation. Sedimentation velocity experiments
were conducted using a Beckman ProteomeLab XL-I (http://www.
beckmancoulter.com) with an An-50 Ti analytical rotor (Beckman).
The samples were equilibrated in buffer B at a concentration of 0.42
mg/ml. All data acquired from this experiment were obtained using
the UV/Vis absorbance detection system (Perkin Elmer, http://www.
perkinelmer.com) on the ultracentrifuge at 280 nm and double sector
12-mm charcoal-ﬁlled Epon centerpieces. The experiment was
conducted at 4 8C at a speed of 40,000 rpm. The data of 300 scans
were analyzed using the LAMM equation in the program SEDFIT [23].
Crystal preparation. To obtain crystals of the AcrB–DARPin
complex, AcrB and the selected AcrB-inhibiting DARPin 1108_19
were puriﬁed separately as described [12]. A small molar excess of the
DARPin with regard to the AcrB monomer was used to prepare the
complex, followed by puriﬁcation on a Tricorn Superdex-200
(Amersham Biosciences) column equilibrated in buffer B. The peak
fractions containing AcrB in complex with the DARPin were
concentrated using a 30-kDa-cutoff concentrator (Amicon Ultra;
Millipore, http://www.millipore.com), exchanged into 10 mM HEPES
(pH 7.5), 50 mM NaCl containing 0.03% (w/v) DDM, and again
concentrated to 13 to 15 mg/ml.
Initial crystallization screening was done in 96-well, sitting drop
crystallization plates (Greiner Bio-One, http://www.greinerbioone.
com). The initial crystals were reﬁned using standard techniques.
The crystals used for data collection appeared within 4 d in 8% PEG
4000, 50 mM ADA (pH 6.5), 200 mM (NH4)2SO4 in a hanging drop
vapor diffusion experiment at 20 8C. For data collection, the crystals
were soaked in six steps for about 15 s in the mother liquid
containing 5% to 30% glycerol and ﬂash frozen into liquid propane.
Data collection, phase determination, and structure reﬁnement.
Data were collected at the Swiss Light Source beamline PX (http://sls.
web.psi.ch/view.php/about/index.html) and processed using the pro-
gram XDS [24]. The crystal belonged to space group P212121, with a
Matthews coefﬁcient VM of 3.8 A˚
3/Da, corresponding to an estimated
water content of 67.7%.
The crystal structure was solved by molecular replacement using
the program PHASER [25,26], with the structure of the AcrB
monomer (Protein Data Bank code 1IWG [6]) used as search model.
A PHASER search with the DARPin E3_5 (Protein Data Bank code
1MJO [13]) as search model did not yield a meaningful solution. The
information obtained from the conventional PHASER protocol for
the three AcrB monomers was sufﬁcient to model one DARPin
molecule into the resulting electron density with the program O [27].
The second DARPin also was positioned in O. Reﬁnement of the
structure was carried out through multiple cycles of manual
rebuilding using the program Coot [28] and reﬁnement using CNS
[29] resulting in a ﬁnal model with an R factor of 22.9 and an Rfree
factor of 27.9. The reﬁned structure of the AcrB–DARPin complex
was validated by the program PROCHECK [30]. Three-dimensional
structural ﬁgures were prepared by using PyMOL [31].
Supporting Information
Figure S1. Surface Plasmon Resonance Analysis of the AcrB–DARPin
Complexes
The binding kinetics of selected DARPins were analyzed using a
BIAcore instrument. Different concentrations of DARPin (2.5, 5, 8,
15, 25, 40, and 60 nM) were applied to a ﬂow cell with immobilized
AcrB for 2 min, followed by washing with buffer ﬂow. The global ﬁt is
indicated in the ﬁgure by black lines.
Found at doi:10.1371/journal.pbio.0050007.sg001 (64 KB DOC).
Figure S2. Sedimentation Velocity Analysis of AcrB and the AcrB–
DARPin Complex Using the LAMM Equation in the Program SEDFIT
(A) AcrB. (B) AcrB–DARPin complex.
Found at doi:10.1371/journal.pbio.0050007.sg002 (27 KB DOC).
Figure S3. Crystal Packing of AcrB–DARPin Complex Crystals
The DARPins (in red) are involved in crystal contacts and thus
account for the different space group and most likely for the high
resolution of the structure.
PLoS Biology | www.plosbiology.org January 2007 | Volume 5 | Issue 1 | e70112
Export Mechanism of Drug Efflux Pump AcrB
Found at doi:10.1371/journal.pbio.0050007.sg003 (902 KB DOC).
Figure S4. Detergent Molecules in the Structure
The structure contains 11 n-dodecyl-b-D-maltoside (DDM) detergent
molecules underlining the quality of the structure.
Found at doi:10.1371/journal.pbio.0050007.sg004 (738 KB DOC).
Table S1. Detailed Interactions of the AcrB–DARPin Complex
Direct hydrogen bonds between AcrB and the bound DARPins
identiﬁed by the program LIGPLOT and the interface accessible
surface area calculated with the Protein-Protein Interaction Server.
Found at doi:10.1371/journal.pbio.0050007.st001 (49 KB DOC).
Table S2. Comparison of the Asymmetric AcrB Structures
Root-mean-square deviations of Ca coordinates calculated by the
program lsqman.
Found at doi:10.1371/journal.pbio.0050007.st002 (41 KB DOC).
Video S1. Comparison of the AcrB–DARPin Complex with Other
Asymmetric AcrB Structures
Superposition of the Ca atoms of the AcrB–DARPin complex (green)
with 2DHH (blue) and 2GIF (pink).
Found at doi:10.1371/journal.pbio.0050007.sv001 (3.2 MB WMV).
Accession Numbers
The atomic coordinates and structure factors of the described
complex have been deposited in the Protein Data Bank (http://www.
rcsb.org) with accession number 2J8S.
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